# Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer

> **NCT07106528** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Extensive-stage Small Cell Lung Cancer (SCLC)
- Small Cell Lung Cancer ( SCLC )

## Interventions

- **DRUG:** Organoid Drug Sensitivity Testing-Guided Therapy
- **DRUG:** Topotecan

## Key facts

- **NCT ID:** NCT07106528
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07106528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07106528, "Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07106528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*